Profilo
Jon Filderman is currently working as the Secretary & Director at Acceleron Pharma, Inc. since 2021.
Prior to this, he worked as a Director at Organon & Co. and as a Manager at Rosetta Inpharmatics LLC.
Posizioni attive di Jon Filderman
| Società | Posizione | Inizio |
|---|---|---|
| ACCELERON PHARMA INC. | Director/Board Member | 19/11/2021 |
Precedenti posizioni note di Jon Filderman
| Società | Posizione | Fine |
|---|---|---|
| ORGANON & CO. | Director/Board Member | 02/06/2021 |
Rosetta Inpharmatics LLC
 Rosetta Inpharmatics LLC BiotechnologyHealth Technology Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ORGANON & CO. | Health Technology |
| Aziende private | 2 |
|---|---|
Rosetta Inpharmatics LLC
Rosetta Inpharmatics LLC BiotechnologyHealth Technology Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jon Filderman
